BWS Financial Inc

BWS provides independent stock specific research focused on companies with distinct value that are going through a special situation where there is a tangible catalyst not priced in. The catalyst can be anything from new product, restructuring, M&A, management change, change in business strategy, etc. BWS’s focus is to understand the change and evaluate the potential return for investors.

BWS utilizes a self formed proprietary approach in discovering stocks by putting great emphasis on deep research. BWS does generate short recommendations following a similar criteria.

Independent Stock Specific Research

Founder, BWS Financial Inc

Hamed Khorsand

Founder

Equity Bottom-Up

Collegium Pharmaceutical / Equity Bottom-Up

<ul type="disc"><li>
Collegium Pharmaceuticals (COLL) announced it would have difficulty in meeting its revenue projections for Xtampza ER when it reported second quarter results. The Company was citing marketing challenges brought on from COVID-19. Non-exclusive payors are not prescribing Xtampza ER as much as forecast.</li></ul> <ul type="disc"><li>Earlier this year we had highlighted how the DEA had reinstituted quota for Schedule II opiate and opioid medication.</li></ul> <ul type="disc"><li>Second quarter revenue was below consensus estimates and COLL has lowered their forecast for Xtampza ER for the rest of the year.</li></ul> <ul type="disc"><li>We have been covering COLL for a year with a negative bias towards its ability to grow Xtampza ER revenue. It has been a slower process than what was expected when we first initiated coverage. We do not believe COVID-19 is playing as much of a factor to the erosion in expectations as COLL’s management states.</li></ul>


Collegium Pharmaceuticals (COLL) announced it would have difficulty in meeting its revenue projections for Xtampza ER when it reported second quarter results. The Company was citing marketing challenges brought on from COVID-19. Non-exclusive payors are not prescribing Xtampza ER as much as forecast. Earlier this year we had highlighted how the DEA had reinstituted quota for Schedule II opiate and opioid medication. Second quarter revenue was below consensus estimates and COLL has lowered their forecast for Xtampza ER for the rest of the year. We have been covering COLL for a year with a negative bias towards its ability to grow Xtampza ER revenue. It has been a slower process than what was expected when we first initiated coverage. We do not believe COVID-19 is playing as much of a factor to the erosion in expectations as COLL’s management states.

Collegium Pharmaceutical

COLL: The Slow Unwind